Skip to content

A Protocol for a Virtual Reality Exposure Therapy for Fear of Flying.

Virtual Reality Exposure Therapy for Fear of Flying: Protocol for a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05939986
Enrollment
84
Registered
2023-07-11
Start date
2023-09-01
Completion date
2024-01-31
Last updated
2023-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aerophobia, Anxiety, Randomized Controlled Trial, Virtual Reality Exposure Therapy

Keywords

Virtual Reality, Fear of Flying, Exposure, Vibrotactile Cues, Anxiety, Presence

Brief summary

This study aims to assess whether adding vibrotactile stimulation to visual and auditory stimulation increases the efficacy of VRET for FoF treatment. Eighty-four participants (18-65 years old) will be assigned to one of three intervention arms, namely the VRET with multimodal feedback (visual, auditory, and vibrotactile; VRET-M), the VRET with bimodal feedback (visual and auditory; VRET-B), or the imagery exposure treatment (IET) without sensory feedback. FoF-related symptoms (primary outcomes) will be measured administering the Fear of Flying Questionnaire-II (QPV-II), the Fear of Flying Scale (FFS), and the Visual Analogic Scale (VAS-A) before and after eight sessions of treatment, and at six- and 12-month follow-ups. Anxiety and the sense of presence experienced during exposure sessions (secondary outcome measures: VAS-A and VAS-P) will also be assessed. It is expected that participants in the VRET-M group will report a further reduction of FoF-related symptomatology after the treatment and at follow-ups compared to participants in the VRET-B and IET groups. Likewise, participants in the VRET-M group are expected to show higher sense of presence levels during exposure sessions in comparison to participants in the VRET-B and IET groups. It is expected that the IET group will report the lowest level of sense of presence and the poorest outcome after treatment and at follow-ups.

Detailed description

Participants who meet the inclusion criteria will be invited to participate in the initial treatment session. They will be also required to purchase a flight ticket during the six months after the end of the treatment. Participants will be treated weekly for eight individual sessions. While the first two sessions involve preparation and training, exposure will be conducted between the third and eighth session. The exposure sessions' structure and content will be the same in all conditions. Nevertheless, the VRET-M group will experience vibrotactile cues, while the VRET-B group will not. Furthermore, the IET group will experience its own subjective imagined environment without any external stimulation.

Interventions

BEHAVIORALVirtual reality-based exposure treatment with multimodal feedback (VRET-M)

The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.

BEHAVIORALVirtual reality-based exposure treatment with bimodal feedback (VRET-B)

The VRET-B group will experience visual and auditive cues in the exposure sessions.

BEHAVIORALImagery exposure treatment (IET)

The IET group will experience its own subjective imagined environment without any external stimulation.

Sponsors

University of Barcelona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Not-blinded study protocol.

Intervention model description

Participants will be assigned to one of three intervention arms, namely the VRET with multimodal feedback (visual, auditory, and vibrotactile; VRET-M), the VRET with bimodal feedback (visual and auditory; VRET-B), or the imagery exposure treatment (IET).

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Subjects who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-5, American Psychiatric Association, APA, 2013) criteria for FoF.

Exclusion criteria

* Individuals with a diagnosis of panic disorder, obsessive-compulsive disorder, or psychotic disorder who have received psychotherapy for their FoF, have been taking prescribed medication for their FoF, or have experienced cardiorespiratory disease or an epilepsy attack will be excluded from the study.

Design outcomes

Primary

MeasureTime frameDescription
Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).Before the exposure treatment.To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.
Anxiety. Administering a Visual Analogue Scale (VAS-A).Before the exposure treatment.To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).

Secondary

MeasureTime frameDescription
Anxiety. Administering a Visual Analogue Scale (VAS-A).Before each exposure session.To what extend I feel anxious now? measured from 0 (absence of anxiety) to 10 (extreme anxiety).
Sense of Presence. Administering the Visual Analogue Scale (VAS-P).Every 2 minutes during each exposure session of 60 minutes.To what extend I feel present now? measured from 0 (absence of sense of presence) to 10 (extreme sense of presence).

Countries

Spain

Contacts

Primary ContactJosé María MR Ribé Viñes, MD
jmribev@gmail.com676022376
Backup ContactMarta MS Ferrer Garcia, PhD
martaferrerg@ub.edu933125114

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026